chailab
@chai_lab
Followers
102
Following
32
Media
92
Statuses
227
Lab of @peterRchai focused on technologies to detect and change the human response to disease
Joined March 2020
New from our collaboration with Pathology @BrighamWomens @BrighamResearch - we assessed the performance of new generation #fentanyl assays to define their performance in clinical care: https://t.co/xTQfjgFRaE
0
1
2
Coming back from another awesome #acmt2024 where we met our newest cohort of the ANTIDOTE program a r25 with @Dr_Carreiro and @NIDAnews. Awesome meeting Junior faculty toxicologists and hearing from POs at NIDA and NIAAA on k awards
0
4
8
Awesome work from our @BostonChildrens @BWHEmergencyMed @Harvard_Tox group on management of severe lead encelopathy #acmt2024
0
2
7
On 4/15 (12:30pm ET) @DrTiffanyGlynn presents her #HIV research in progress! @MGHPsychiatry @transSOCIALfl @TMPInc_org @ourtranshealth @FirstEventConf @BHCHP @BWHEmergencyMed @MGHPsychiatry @harvardmed #transwomen #HealthEquity #substanceusedisorders Info@ https://t.co/nIwYXsq7oO
0
1
2
Proud to join colleagues across the world to develop cannabis/cannabinoid guidelines for adults with cancer with @ASCO @DanaFarber @BrighamResearch: https://t.co/bUC8NhPWUW
0
0
1
Smartphone and Wearable Device-Based Digital Phenotyping to Understand Substance use and its Syndemics. READ IT HERE in @JMT_tweets >> https://t.co/U3n1ihIPlN
@PeterRchai @harvard_tox @brighamwomens @chai_lab @Dr_Carreiro @FenwayHealth @jslee_phd @k_deux_v
Smartphone and Wearable Device-Based Digital Phenotyping to Understand Substance use and its Syndemics | @acmtmedtox READ IT HERE >> https://t.co/YOFadWM3R4
0
3
1
One of the most important things we wanted to do here was break down the #stigma barriers that individuals will substance use won't engage in technologies to address comorbid disease. This analysis shows that sub use was not associated with MSM willingness to use #digitalpills
0
1
0
From our lab with @DrTiffanyGlynn @jslee_phd and collaborators @khmayer1 @FenwayHealth @FordhamEthics work in @PLOSDigiHealth on how MSM on #PrEP think about #digitalpills and #digitalphenotyping
https://t.co/XsTH5TeHdn
1
3
2
Excited to share our new manuscript on formative usability and acceptability of digital pill systems for #heartfailure #adherence measurement using #digitalpills in @jmirpub
https://t.co/rSLjjsoLe2
cardio.jmir.org
Background: Heart failure (HF) affects 6.2 million Americans and is a leading cause of hospitalization. The mainstay of the management of HF is adherence to pharmacotherapy. Despite the effectiveness...
0
2
2
Excited to participate with our close colleagues @MIT on the new @ARPA_H initiative to advance our knowledge and treatment of metabolic disease! @BWHEmergencyMed
https://t.co/MZ8fuIf35c
news.mit.edu
MIT researchers have been awarded $65.6 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop ingestible devices that could be used to treat diabetes, obesity, and other...
0
3
3
Discussing work by @DrTiffanyGlynn on understanding strategies to reach individuals with hiv risk using technologies in the emergency dept @HICSSnews #hicss57
0
2
1
Dr. Lee @jslee_phd presenting on work on #digitalpills and their application in #hiv #adherence monitoring in South Africa. In collaboration with @UCT_news #hicss57 @HICSSnews
0
2
3
Work with our colleagues @FenwayHealth on perspectives of sexual networking of MSM identifying as persons of color during COVID-19 https://t.co/OeScv5EOH4
pubmed.ncbi.nlm.nih.gov
Men who have sex with men and identify as persons of color (MSM of color) are significantly impacted by HIV in the United States. The COVID-19 pandemic may have disproportionately exacerbated...
0
2
1
New work from our group led by @Dr_GoldiTox on updates in current management of beta blocker and calcium channel blocker toxicity in European Heart Journal @ESC_Journals: https://t.co/PX3mdgTCy6
0
5
17
Although fentanyl is now the dominant driver of the U.S. opioid epidemic, our health care system has struggled to adapt toxicology screening practices to this reality. Read the Perspective by Drs. @BrianBarnettMD, @PeterRchai & Joji Suzuki:
0
12
13
our perspective on increasing access to #fentanyl testing and increasing access to point of care testing for those with #oud @NEJM
nejm.org
Although fentanyl is now the dominant driver of the U.S. opioid epidemic, our health care system has struggled to adapt toxicology screening practices to this reality.
0
6
16